ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2022

Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS.

Jens Kuhle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.